<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05618496</url>
  </required_header>
  <id_info>
    <org_study_id>PT-EPI-1_09-20</org_study_id>
    <nct_id>NCT05618496</nct_id>
  </id_info>
  <brief_title>Multi-centre, Open-label, First-in-man Study With Epipad Used in Adult Patients</brief_title>
  <official_title>Multi-centre, Open-label, First-in-man Study With Epipad Used in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Contipro Pharma a.s.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Contipro Pharma a.s.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to confirm safety of a new product - Epipad. The main&#xD;
      impact of the device is to provide good environment for the healing of chronic wounds and&#xD;
      wounds in the last healing phase (granulation and epithelisation).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 26, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the wound dimensions (width x length)</measure>
    <time_frame>Week 3</time_frame>
    <description>Change in the wound dimensions from baseline</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Wound</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sodium Hyaluronate Lyophilizate</intervention_name>
    <description>Device is placed directly onto the treated wound. The wound should be cleaned with antiseptic solution prior to the device administration. The device is fixed on the wound by secondary dressing: e.g. plaster, compression.</description>
    <other_name>Epipad</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient suffered from superficial wound of different etiology&#xD;
&#xD;
          -  Wounds in terminal phase of healing&#xD;
&#xD;
          -  Wounds without visible sign of infection&#xD;
&#xD;
          -  Max. size of the wound: 10 x 20 cm (i.e. two pieces of the product)&#xD;
&#xD;
          -  Duration of wound treatment of at least 6 weeks&#xD;
&#xD;
          -  Subject willing and able to provide written informed consent&#xD;
&#xD;
          -  Ability to communicate well with the investigator in local language, and to understand&#xD;
             and comply with the requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Sloughy or necrotic wound bed&#xD;
&#xD;
          -  Severely contaminated or infected wound&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Pregnant or lactating woman&#xD;
&#xD;
          -  Subject in terminal stage of living&#xD;
&#xD;
          -  Subject with cancer disease&#xD;
&#xD;
          -  Subject with known hypersensitivity or allergy to any component of the investigational&#xD;
             device&#xD;
&#xD;
          -  Subject participating in other interventional clinical trial&#xD;
&#xD;
          -  Alcohol and/or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fakultni nemocnice u sv. Anny</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levitovo centrum nasledne pece</name>
      <address>
        <city>Hořice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vojenska nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vsetinska nemocnice</name>
      <address>
        <city>Vsetín</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 9, 2022</study_first_submitted>
  <study_first_submitted_qc>November 9, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 9, 2022</last_update_submitted>
  <last_update_submitted_qc>November 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

